Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma
1/27/2026
1:00 PM - 2:00 PM Eastern


Location: This is a live virtual event





Event Description

Fluorescence in situ hybridization (FISH) remains the gold standard clinical assay to detect genetic abnormalities in multiple myeloma (MM). However, FISH panel design, use of conventional chromosome banding analysis and reporting practices have been reported to vary among laboratories. Therefore, standardization in FISH testing and reporting practices is needed to improve report clarity and avoid misinterpretation.

In this webinar, Dr. Linda Baugn, will introduce the recommendations published by the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group, which is comprised of cytogenetic laboratory directors and clinical investigators with expertise in the diagnosis, risk stratification, and treatment of multiple myeloma. Prior to developing these consensus recommendations, they performed a full literature review and conducted a survey of 102 oncologists to assess current variations and challenges in MM cytogenetic/FISH testing and reporting. The guidelines establish best practices for the optimization of FISH panel selection, and recommendations for standardized reporting of cytogenetic results to align with the 2025 International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) Updated Risk Stratification.

Speaker: Linda Baughn, PhD, FACMG

Learning Objectives: At the end of this webinar, participants will be able to:

  1. Describe the current variability in fluorescence in situ hybridization (FISH) panel design, chromosome banding analysis, and reporting practices for multiple myeloma across clinical laboratories.
  2. Apply the consensus-based recommendations from the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group to optimize FISH panel selection and standardize cytogenetic reporting in multiple myeloma.
  3. Integrate standardized FISH testing and reporting practices with the 2025 International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) Updated Risk Stratification to improve diagnostic clarity and patient management.